Navigation Links
Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
Date:10/4/2010

HOBOKEN, N.J., Oct. 4 /PRNewswire/ -- Octapharma USA has launched a comprehensive Web site for wilate® at www.wilateusa.com to provide von Willebrand disease healthcare professionals and patients with easily accessible information, news and updates. The U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate® (von Willebrand Factor/Factor VIII Concentrate, Human), the first replacement therapy developed specifically for von Willebrand Disease (VWD).

The web resource provides the VWD community with a dynamic and educational on-line experience designed to inspire site visitors to acquire the knowledge and seek additional information on wilate® from their healthcare provider or Octapharma. According to the National Institutes of Health, VWD is the most common inherited bleeding disorder and occurs in about 1 out of every 100 to 1,000 people.

The FDA has approved wilate® for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe VWD as well as in patients with mild or moderate forms of the illness in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for over 27 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com.


'/>"/>
SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
5. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016  As a teenager, an active and ... which damaged his heart. He continued enjoying sports and ... 2013, Shepherd,s heart was giving out and he was ... 20, 2013, the Mesa, Arizona ... Like a heart transplant, the SynCardia TAH-t is the ...
(Date:5/3/2016)... watching a film or TV show in high definition, you may not be familiar with ...  is a renowned authorized reseller of the medical industry,s top brands as well as a ... ... ... Although initially introduced ...
(Date:5/3/2016)... May 3, 2016 Pharmaceutical giant ... million to a woman who says its talc-based powder ... Gloria Ristesund $5 million in compensatory damages ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This ... the company. In February, the same court awarded $72 ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... Expert mattress researchers and testers ... in September, 2014 Sleepopolis has resided at Sleepopolis-mattress-reviews.com . The move signals ... mattress toppers, bed frames, and more. , Founder and Editor-in-Chief Derek Hales said, ...
(Date:5/6/2016)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a new ... the Bible about helping to stop cancer. Yisrayl says there are too many suffering and ... health and science industries will pay close attention and take action. The Pastor says that ...
(Date:5/6/2016)... Lehi, Utah (PRWEB) , ... May 06, 2016 ... ... Career Step, an online provider of career-focused education and corporate training, and the ... families, are pleased to announce Maritza Aquino as the second full-tuition scholarship recipient ...
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, DSc, RN, ... Institute of the South announced today that Dr. Robert Menuet, Interventional Cardiologist with ... Intravascular Ultrasound Guided Coronary Atherectomy. , This procedure involves the removal ...
(Date:5/6/2016)... Washington, DC (PRWEB) , ... May 06, 2016 ... ... Blum, Executive Vice President at CareFirst Blue Cross BlueShield and Former Principal Deputy ... Officer at CareMore - an Anthem Company; Steve Ondra, MD, Chief Medical Officer ...
Breaking Medicine News(10 mins):